0838 GMT - Regulatory clearance of Novo Holdings' planned acquisition of Catalent is a significant positive for Novo Nordisk, Intron Health analyst Naresh Chouhan writes. Novo Holdings will buy U.S. contract drug maker Catalent before selling three of Catalent's production sites to Novo Nordisk. The deal has not been challenged by the Federal Trade Commission, paving the way for the deal to close in the coming days. "This is a very significant positive in our view and has both long-term and short-term upside ramifications." Intron Health believes the extra capacity will allow Novo Nordisk to boost Wegovy production and give it considerable manufacturing might which could also help deter competitors from investing in biosimilars. Shares rise 2.1% to 769.70 Danish kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
December 16, 2024 03:38 ET (08:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。